Publicaciones en colaboración con investigadores/as de University of Texas Southwestern Medical Center (73)

2024

  1. Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients

    The Lancet Infectious Diseases, Vol. 24, Núm. 1, pp. e59-e68

2023

  1. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

    Nature Medicine, Vol. 29, Núm. 7, pp. 1867-1876

  2. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

    The Lancet, Vol. 402, Núm. 10415, pp. 1835-1847

  3. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib

    European urology, Vol. 83, Núm. 3, pp. 200-209

  4. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

    Annals of Oncology, Vol. 34, Núm. 10, pp. 885-898

  5. Orthostatic Tremor

    Contemporary Clinical Neuroscience (Springer Nature), pp. 247-269

2022

  1. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function

    Kidney International, Vol. 101, Núm. 1, pp. 174-184

  2. Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy

    RMD Open, Vol. 8, Núm. 1

  3. Acute onset movement disorders in diabetes mellitus: A clinical series of 59 patients

    European Journal of Neurology, Vol. 29, Núm. 8, pp. 2241-2248

  4. An open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension

    Pulmonary Circulation, Vol. 12, Núm. 1

  5. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

    Cancer, Vol. 128, Núm. 11, pp. 2085-2097

  6. ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19

    Scientific Data, Vol. 9, Núm. 1

  7. Performance of the American Heart Association/American College of Cardiology/Heart Rhythm Society versus European Society of Cardiology guideline criteria for hospital admission of patients with syncope

    Heart Rhythm, Vol. 19, Núm. 10, pp. 1712-1722

  8. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

    Journal for immunotherapy of cancer, Vol. 10, Núm. 2

2021

  1. Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial

    Clinical Infectious Diseases, Vol. 73, Núm. 11, pp. 2009-2022

  2. Components determining the slowness of information processing in parkinson’s disease

    Brain and Behavior, Vol. 11, Núm. 3

  3. Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials

    Journal of the American College of Cardiology, Vol. 77, Núm. 19, pp. 2366-2377

  4. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults with Overweight or Obesity: The STEP 4 Randomized Clinical Trial

    JAMA - Journal of the American Medical Association, Vol. 325, Núm. 14, pp. 1414-1425

  5. Effects of dapagliflozin on mortality in patients with chronic kidney disease: A pre-specified analysis from the DAPA-CKD randomized controlled trial

    European Heart Journal, Vol. 42, Núm. 13, pp. 1216-1227

  6. Worldwide Survey of COVID-19-Associated Arrhythmias

    Circulation: Arrhythmia and Electrophysiology, Vol. 14, Núm. 3, pp. E009458